CD33 and acute myeloid leukemia: In contrast, in the two groups of AML patients separated by serum metabolomics, there were no significant differences in the expression rates of CD34, CD13, CD33, CD15, or CD117 antigens (Figure 5, Supplementary Figure.S1).